Ph.D. molecular pharmacologist building new scientific capabilities from emerging ideas—turning mechanisms into platforms, prototypes, patents, and product decisions across therapeutics and consumer health.
I identify scientific opportunities, build the capabilities needed to test them, and translate the evidence into innovations, programs, and decisions.
I turn emerging scientific questions into working capabilities—from mechanistic discovery and assay development to biofilm, microbiome, and 3D-tissue platforms—then use the evidence to shape therapeutics, products, claims, and innovation strategy.
I translate complex data into clear, credible narratives - claims substantiation, technical briefs, evidence synthesis, and KOL-ready insight - adapting depth for scientists, regulators, commercial teams, and leadership.
I use AI-assisted development to rapidly prototype scientific software and computational workflows—from structural modeling and protein-interaction analysis to data pipelines and operational systems—turning ideas into testable tools without losing scientific rigor.
From a regulatory blind spot to a global R&D capability
Traditional germ-protection testing largely evaluates microorganisms in planktonic states, despite biofilms and structured microbial communities being major sources of persistence in real-world environments. I identified the opportunity to move beyond planktonic kill and establish a platform for understanding, disrupting, and selectively shaping microbial communities.
I built the capability from the ground up—developing assays, SOPs, model systems, and the scientific knowledge base needed for internal and external execution. The platform was adopted across global R&D, formulation, claims, and regulatory teams, enabling new biofilm-focused innovation opportunities across consumer-health applications.
Mechanism → therapeutic strategy → enabling technology → IP
Not all β-lactams synergized equally with FtsZ inhibition in resistant S. aureus. I investigated why, connecting β-lactam target affinity with disruption of the spatial organization required for bacterial cell-wall synthesis and resistance.
Using engineered fluorescent MRSA strains, protein-localization studies, binding-affinity measurements, and antimicrobial synergy assays, I helped establish how disrupting FtsZ-dependent division compromises the coordination of penicillin-binding proteins and restores susceptibility to selected β-lactams—creating a strategy for pairing new inhibitors with established antibiotics.
That same structure-driven program also led to a new tool: recognizing an exposed chemical position on an FtsZ inhibitor enabled fluorophore conjugation and the development of patented fluorescent probes for visualizing bacterial division in living cells.
Clinical ecology → reconstructed tissue → translational claims
Microbiome sequencing can describe an ecological state, but product innovation requires models that can test how interventions affect the host–microbe system. I led translational programs connecting clinical microbiome observations with experimentally tractable human-tissue models.
For vulvar health, we established a reconstructed 3D tissue model and incorporated relevant microbial communities to better represent the local biological environment. As study lead, I defined the scientific strategy and experimental questions while CRO partners executed key studies.
The resulting platform connected clinical microbiome data with controlled experimental evidence, supporting the development of new product hypotheses and scientifically differentiated claims.
I build what science needs next.
I am a molecular pharmacologist and scientific innovation leader who works at the point where an interesting biological observation becomes a capability, a prototype, or a program. My work spans mechanistic discovery, translational models, antimicrobial and microbiome science, and the technologies needed to move an idea from hypothesis toward therapeutic or product impact.
My scientific foundation is mechanistic: understand why a biological system behaves the way it does, then use that understanding to create something new. That approach has taken me from decoding antibiotic synergy and bacterial cell division to building biofilm and host–microbiome platforms designed around real translational questions.
I enjoy creating new programs, but scientific leadership also means knowing what should not advance. I have recommended stopping concepts when biological evidence did not support meaningful benefit and ended technically successful prototypes when the legal or operating path made continued investment difficult to justify. For me, innovation is not about keeping every idea alive—it is about finding the ones worth building.
The strongest evidence has little impact if it cannot move across disciplines. I work comfortably between scientists, external partners, regulatory teams, formulators, commercial stakeholders, and leadership—changing the level of technical depth without changing the integrity of the science.
I am most energized by emerging scientific problems where the capability to answer the question does not yet exist. That includes new translational platforms, microbial and host–microbe systems, next-generation therapeutics, and AI-enabled scientific tools that make discovery faster and more experimentally intelligent.
Whether the output is a drug combination, a biological model, a consumer-health platform, a patent, or a piece of scientific software, the pattern is the same: identify the opportunity, build the capability, test it rigorously, and decide whether it deserves to scale.
From discovery through patent to commercialization, listed by release year with the newest work first.
Characterization of vulvar microbiome ecology across life stages, health status, and functional signatures.
Novel fluorescent probes designed to target the FtsZ protein for real-time visualization of division machinery. Licensed and commercialized via MilliporeSigma.
Discovery of a benzamide FtsZ inhibitor with strong bactericidal activity and in vivo efficacy against multidrug-resistant MRSA.
Demonstrates how FtsZ inhibition can restore and potentiate beta-lactam performance against MRSA.
Identification of MreB-targeting small molecules with antibacterial activity against Gram-negative pathogens.
Mechanistic study connecting FtsZ inhibition to altered localization of penicillin-binding proteins in MRSA.
Structure-guided probe design enabling visualization of FtsZ across clinically relevant pathogens.
Identifies beta-lactams with high PBP2 affinity that maximize synergy with FtsZ inhibition against MRSA.
Insights on microbiology, scientific practice, and the systems that shape them.
Exploring the mechanistic models driving modern drug discovery and how systems-level thinking reshapes translational science.
I build and lead capabilities that connect mechanistic discovery, translational models, emerging technology, and portfolio decisions—from the first scientific question to a platform others can use.
Using molecular and cellular mechanisms to uncover new intervention points, explain differential response, and design therapeutic strategies—from target validation and drug combinations to resistance-breaking approaches.
Designing experimental systems around microbial communities rather than isolated organisms—from biofilms and host–microbe interactions to microbiome modulation and emerging approaches such as bacteriophage-enabled control.
Building experimental bridges between discovery and real-world biology using reconstructed tissues, clinically informed microbial communities, biomarkers, and fit-for-purpose studies designed around the decision the program ultimately needs to make.
Rapidly prototyping computational and operational tools that expand what scientists can test—from protein structure and interaction workflows to automated data pipelines, scientific software, and AI-assisted decision systems.
I’m interested in opportunities to lead scientific platforms, incubate emerging technologies, and translate new biology into therapeutics, products, and scalable capabilities.